Table 3.
Baseline characteristics of patients treated with local ablation, transarterial treatment or palliative treatment.
| Bud-negative (N = 131) | Bud-positive (N = 81) | High TSR (<50%) (N = 172) | Low TSR (≥50%) (N = 40) | |
|---|---|---|---|---|
| Postoperative chemo- or radiotherapy | 30 (22.9%) | 17 (21.0%) | 37 (21.5%) | 10 (25.0%) |
| Stage | ||||
| Stage I | 48 (36.6%) | 36 (44.0%) | 68 (39.5%) | 16 (40.0%) |
| Stage II | 21 (16.0%) | 10 (12.3%) | 27 (15.7%) | 4 (10.0%) |
| Stage III | 36 (27.5%) | 22 (27.2%) | 48 (27.9%) | 10 (25.0%) |
| Stage IV | 24 (18.3%) | 12 (14.8%) | 28 (16.3%) | 8 (20.0%) |
| Tumour localisation | ||||
| Right lobe | 65 (49.6%) | 31 (38.3%) | 79 (45.9%) | 17 (42.5%) |
| Left lobe | 14 (10.7%) | 16 (19.8%) | 25 (14.5%) | 5 (12.5%) |
| Both lobes | 51 (38.9%) | 34 (42.0%) | 67 (39.0%) | 18 (45.0%) |
| Unifocal tumour | 59 (45.0%) | 37 (45.7%) | 77 (44.8%) | 19 (47.5%) |
| Tumour grade | ||||
| Grade I | 39 (30.5%) | 25 (30.9%) | 51 (30.2%) | 13 (32.5%) |
| Grade II | 74 (57.8%) | 45 (55.6%) | 98 (58.0%) | 21 (52.5%) |
| Grade III | 15 (11.7%) | 11 (13.6%) | 20 (11.8%) | 6 (15.0%) |
| Tumour size (mm), median (IQR) | 75.0 (40.0–110.0) | 65.0 (40.0–100.0) | 70.0 (40.6–11.0) | 72.5 (36.3–100.0) |
No significant differences were observed between the groups.